Advancing our knowledge of risk factors
Center for Geriatric Medicine leads inpatient care of fragility fractures
Results of the largest population-based study to date
Benefit/AFF risk ratio favors 3–5 years of treatment
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
If denosumab is stopped, it should be replaced with another osteoporosis treatment
Romosozumab builds more bone than any previous medication
Dual-acting drug increases bone formation while decreasing resorption
What the updated evidence-based guidelines mean for your patients
Romosozumab significantly reduced fracture risk, though close follow-up is required
Holly L. Thacker, MD, weighs in